Novo Nordisk Moves Amycretin Into Phase 3 Trials For Weight Management, Becomes Europe's Largest Company - Novo Nordisk (NYSE:NVO)

Novo Nordisk Moves Amycretin Into Phase 3 Trials For Weight Management, Becomes Europe's Largest Company - Novo Nordisk (NYSE:NVO)

Novo Nordisk A/S (NYSE:NVS) announced Thursday that it will advance subcutaneous and oral amycretin into phase 3 development in weight management. Amycretin is developed for subcutaneous and oral administration. The decision to advance subcutaneous and oral amycretin into phase 3 is based on feedback received from regulatory authorities following end-of-phase 2 interactions for subcutaneous and oral amycretin in weight management. Novo Nordisk p…

Novo, searching for a spark, plans late-stage trials for amylin drug

The Danish drugmaker, which is grappling with a share decline and competition from Eli Lilly, unveiled planned trials of an obesity medication that works differently than its popular Wegovy.

Novo Nordisk plans to start late-stage trials of obesity drug amycretin ...

Novo Nordisk Plans to Start Late-Stage Trials for Experimental Obesity ...

Novo to begin late-stage trial to test new obesity drug (NVO)

Novo Nordisk (NVO) plans to start a late-stage clinical program next year to test oral and injectable forms of its new obesity therapy amycretin. Read more here.

Novo Nordisk to advance subcutaneous and oral amycretin for weight management into phase 3 clinical development

**media[653456]**